BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Director V Bryan Lawlis sold 6,400 shares of the company’s stock in a transaction that occurred on Friday, July 22nd. The shares were sold at an average price of $95.01, for a total value of $608,064.00. Following the sale, the director now directly owns 20,260 shares in the company, valued at $1,924,902.60. The transaction was disclosed in a filing with the SEC, which is available at this link.
Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) traded down 0.83% during midday trading on Tuesday, reaching $92.02. The company’s stock had a trading volume of 2,160,802 shares. The stock has a 50-day moving average of $85.05 and a 200 day moving average of $83.34. The company’s market cap is $14.94 billion. BioMarin Pharmaceutical Inc. has a 12 month low of $62.12 and a 12 month high of $148.30.
BioMarin Pharmaceutical (NASDAQ:BMRN) last released its quarterly earnings results on Thursday, April 28th. The company reported ($0.53) earnings per share for the quarter, topping the consensus estimate of ($0.85) by $0.32. The firm earned $236.70 million during the quarter, compared to the consensus estimate of $240.21 million. During the same period in the previous year, the company posted ($0.43) EPS. The company’s revenue for the quarter was up 16.7% compared to the same quarter last year. On average, analysts predict that BioMarin Pharmaceutical Inc. will post ($2.16) earnings per share for the current fiscal year.
Several equities research analysts recently issued reports on BMRN shares. Cowen and Company reissued a “buy” rating on shares of BioMarin Pharmaceutical in a research report on Sunday, April 17th. Jefferies Group reaffirmed a “buy” rating and issued a $116.00 target price (down from $120.00) on shares of BioMarin Pharmaceutical in a research report on Friday, April 8th. Piper Jaffray Cos. reaffirmed a “buy” rating on shares of BioMarin Pharmaceutical in a research report on Wednesday, April 20th. Credit Suisse Group AG reaffirmed a “buy” rating and issued a $114.00 target price on shares of BioMarin Pharmaceutical in a research report on Friday, April 29th. Finally, Royal Bank Of Canada reaffirmed a “buy” rating on shares of BioMarin Pharmaceutical in a research report on Tuesday, May 31st. Three research analysts have rated the stock with a hold rating and nineteen have given a buy rating to the company. BioMarin Pharmaceutical presently has a consensus rating of “Buy” and a consensus target price of $123.25.
BioMarin Pharmaceutical Inc (BioMarin) develops and commercializes pharmaceuticals for various diseases and medical conditions. The Company’s product portfolio consists of approximately five approved products, and multiple clinical and pre-clinical product candidates. Its approved products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Aldurazyme (laronidase) and Firdapse (amifampridine phosphate).
